Progesterone and statins for young women with early endometrial cancer or atypical hyperplasia
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether adding a statin to progesterone therapy helps young women with early endometrial cancer or atypical endometrial hyperplasia who want to preserve their fertility. It aims to find a better treatment option for those who may not respond well to progesterone alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have either atypical endometrial hyperplasia or stage IA, grade 1 endometrioid adenocarcinoma that hasn't spread outside the uterus.
- You are 45 years old or younger and want to keep your ability to have children.
- You have not taken any cholesterol-lowering medications, even if your cholesterol is normal or abnormal.
- You are either newly diagnosed and haven't used progesterone or similar hormones, or you've had one or two treatment cycles (12 to 24 weeks) with some response.
- You do not have severe liver or kidney disease, other cancers, or conditions like blood clots, stroke, or heart attack.
- You do not drink heavily (more than 20 grams of alcohol per day) or smoke heavily (more than 15 cigarettes per day).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the weight-loss drug orlistat to standard hormone therapy can help shrink early-stage endometrial cancer or precancerous changes, so you can avoid having your uterus removed and still try for a baby later.
This study tests whether a common blood pressure medication called amlodipine can help treat early-stage endometrial cancer in younger women who want to preserve their fertility. It may be an alternative to hormone therapy, with fewer side effects.
This study looks at small lab samples taken from early endometrial cancer to see how sensitive the tumor is to progesterone treatment. It may help doctors choose the safest treatment that preserves fertility and the uterus for the right patients.
This Phase 3 study tests whether taking atorvastatin (a cholesterol-lowering medicine) can improve outcomes for women with estrogen-receptor–positive breast cancer. It may help by affecting cancer-related pathways and reducing risk of recurrence or progression.
This trial tests whether combining two hormone medicines can treat early endometrial (uterine) cancer while helping preserve the uterus and future fertility. You may be eligible if your cancer is early and limited, with no spread seen on scans, and you can safely take these medicines.
This trial tests whether a cholesterol medicine (a statin) can lower the risk of heart damage in people receiving HER2-targeted breast cancer therapy. If you qualify, you may be given a statin and followed with heart tests and blood work to watch for safety and benefit.
Hear when a new Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.